glp-1 weight loss drug news today Alarming rise in overdoses GLP-1 weight-loss drug popularity reaches
Description
Cereb Cortex
J Obes 2013
doi: 10.1517/17460441.2014.942638 67 HorowitzMRaynerCKJonesKL
In a phase II study of the long-acting GLP-1RA efpeglenatide (4 mg once weekly, 6 mg once weekly, 6 mg once every 2 weeks, and 8 mg once every 2 weeks), patients with obesity and without diabetes had statistically significant reductions in body weight compared with placebo after 20 weeks of treatment (differences in least squares means were 6.3 to 7.2 kg
Although long-acting GLP-1 receptor agonists commonly cause nausea, the side effect is typically short-lived, and patients generally tolerate the treatment well
